ArticleThe protein journal2026
Computational Identification of IL-17 a Small-Molecule Inhibitors as Potential Therapeutics for Plaque Psoriasis Through e-Pharmacophore Screening, Molecular Docking, and Molecular Dynamics Simulation.
Article in The protein journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plaque psoriasis is a long-term skin disease driven by the immune system, impacting around 1-3% of people worldwide. Despite the availability of various treatment options, the limitations in effectiveness, side effects, and long-term response underscore the necessity for enhanced therapeutic strategies. Focusing on the interleukin-17 (IL-17) pathway offers a promising strategy for treating plaque psoriasis. In this research, established co-crystallized peptide-derived inhibitors (PDB IDs: 5HI3, 5HI4, and 5HI5) were utilized to create energetically optimized pharmacophore models, which were then used for virtual screening of chemical libraries, resulting in 4,923 potential hit compounds. Molecular docking based on structure and induced-fit docking were subsequently conducted on IL-17 A to pinpoint potential lead compounds exhibiting advantageous binding orientations and interactions with essential active-site residues. The selected protein-ligand complexes' stability and dynamic behavior were examined through molecular dynamics (MD) simulations, which were complemented by root mean square deviation (RMSD), radius of gyration (RoG), principal component analysis (PCA), and dynamic cross-correlation matrix (DCCM) analyses. The MD simulations revealed that the selected leads retained consistent interactions in the IL-17 A binding pocket, with C2 and C3 demonstrating especially advantageous protein structural stability, while C3 displayed the most stable ligand behavior. PCA uncovered unique collective movements within the complexes, while DCCM analysis showed specific correlated and anti-correlated residue movements linked to protein conformational dynamics. Ongoing protein-ligand interactions further confirmed the stable placement of the chosen compounds within the binding site. In summary, the combined pharmacophore-based virtual screening, molecular docking, MD, PCA, and DCCM analyses discovered promising lead compounds exhibiting advantageous binding stability and dynamic behavior, offering a structural foundation for their subsequent experimental validation and potential advancement as therapeutic candidates for plaque psoriasis.
Indexed as
Identifiers
42862452What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.